marked.bio

anti-EGFR antibody · antibody

JMT101

2 active trials across 2 of our biomarkers, targeting EGFR. Not approved for any biomarker on marked.bio yet.

Counts only trials that select patients by one of the biomarkers on marked.bio, not every trial of this drug.

Biomarkers

BiomarkerActive trialsAll trialsFurthest active phase
EGFR exon 19 deletion / L858R 1 1 Phase 2
EGFR exon 20 insertion 1 3 Phase 3

Sponsors

Industry sponsors leading active biomarker-selected trials of JMT101.

  1. Shanghai JMT-Bio 2

Trials

2 of 4 trials shown

  1. JMT101 in Combination With Osimertinib, Versus Cisplatin-pemetrexed in Participants With Locally Advanced or Metastatic Non-small Cell Lung Cancer (NSCLC) Characterized by Epithermal Growth Factor Receptor (EGFR) Exon 20ins Mutations

    Not yet recruiting Phase 3 Shanghai JMT-Bio Started 2024Primary completion 2027-03 NCT06380348

    JMT101osimertinibcisplatinpemetrexed

    For central laboratory confirmation of EGFR exon 20 insertion mutation with tumour tissue/blood sample.

    EGFR exon 20 insertionStatus may be outdated, last updated 2024-04-23Local Advanced or Metastatic NSCLC

  2. JMT101 Combined With Osimertinib in Patients With Stage Ⅲb-Ⅳ Non-small Cell Lung Cancer (NSCLC) Characterized by Epithermal Growth Factor Receptor (EGFR) Common Mutations

    Active, not recruiting Phase 2 Shanghai JMT-Bio Started 2021Primary completion 2023-05 NCT06391944

    JMT101osimertinib FDA EU

    … to the 8th edition of the AJCC TNM staging criteria) or metastatic (Stage IV) harbouring EGFR common mutation with tumour tissue/blood sample.

    EGFR exon 19 deletion / L858RStatus may be outdated, last updated 2024-04-30Local Advanced or Metastatic NSCLC, Harboring EGFR Common Mutation